Elevance Health Inc

Elevance Health’s Q4 2025 earnings preview shows modest EPS and revenue growth, driven by cross‑benefit bundling and cost‑control, while facing telehealth and regulatory risks.

Elevance Health’s analyst upgrades boost target prices, spotlighting Medicare Advantage as a key growth driver amid rising regulatory scrutiny and market volatility.

Elevance Health’s rise amid CAQH’s takeover, scale pressure, and investor momentum: how data‑centric strategy can boost margins and outpace U.S. insurers.

Elevance Health’s new commentary explains how it’s reshaping employer‑, individual‑, Medicaid and Medicare plans with value‑based contracts, tiered networks and tech‑driven managed care to stay compliant, curb premiums and gain AM Best’s latest cred…

Elevance Health’s 2025 strategy: plan overhaul, rating downgrade insights, and Amy Schulman’s board boost—what it means for investors and future growth.

Elevance Health strengthens governance with former Pfizer GC Amy Schulman, boosts its credit rating per AM Best, and outlines a forward‑looking plan to improve patient care, digital services, and financial resilience in a rapidly evolving health‑car…

Elevance Health strengthens governance with former Pfizer counsel Amy Schulman on its board, boosting audit and finance oversight while expanding community maternal‑health initiatives and positioning for growth in the U.S. health‑insurance market.

Elevance Health Inc., a leading US health insurance provider, has shown robust growth over the past five years, with a 21.9% cumulative return for investors, outpacing the S&P 500 index, and a projected 13% upside over the next 12 months, according …

Elevance Health Inc. has seen a modest increase in its share price due to favorable analyst coverage and a renewed emphasis on the Affordable Care Act, but faces operational challenges and regulatory uncertainty in the US healthcare delivery landsca…

Elevance Health Inc. faces significant challenges in the healthcare industry, including regulatory pressure, competitive landscape, and financial constraints, which may impact its long-term trajectory and valuation.